General Information of Drug (ID: DMVPZBE)

Drug Name
Iloprost
Synonyms
Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Approved [1]
Pulmonary hypertension BB01 Approved [2]
Systemic sclerosis 4A42 Approved [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 360.5
Logarithm of the Partition Coefficient (xlogp) 2.8
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 63% []
Clearance
The clearance of drug is 20 mL/min/kg in healthy subjects []
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 - 30 minutes [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0018 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.4% [4]
Vd
The volume of distribution (Vd) of drug is 0.7-0.8 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [3]
Chemical Identifiers
Formula
C22H32O4
IUPAC Name
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
Canonical SMILES
CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
InChI
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
InChIKey
HIFJCPQKFCZDDL-ACWOEMLNSA-N
Cross-matching ID
PubChem CID
5311181
ChEBI ID
CHEBI:63916
CAS Number
78919-13-8
DrugBank ID
DB01088
TTD ID
D05ZTH
VARIDT ID
DR00099
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Agonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 2A1 (SLCO2A1) DT021JD SO2A1_HUMAN Substrate [7]
Organic anion transporting polypeptide 3A1 (SLCO3A1) DTVNRXW SO3A1_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiopoietin-1 (ANGPT1) OTVZ1NG3 ANGP1_HUMAN Gene/Protein Processing [9]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Gene/Protein Processing [9]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Gene/Protein Processing [10]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Gene/Protein Processing [9]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [11]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Gene/Protein Processing [11]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Gene/Protein Processing [11]
Prostacyclin receptor (PTGIR) OTWTABYM PI2R_HUMAN Protein Interaction/Cellular Processes [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pulmonary arterial hypertension
ICD Disease Classification BB01.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin E2 receptor EP2 (PTGER2) DTT PTGER2 2.77E-06 1.15 1.37
Organic anion transporting polypeptide 3A1 (SLCO3A1) DTP OATP3A1 9.66E-01 2.27E-01 3.78E-01
Organic anion transporting polypeptide 2A1 (SLCO2A1) DTP OATP2A1 6.15E-01 -3.02E-02 -2.83E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Iloprost (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Iloprost and Cilostazol. Arterial occlusive disease [BD40] [13]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Iloprost and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [13]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Iloprost and Levomilnacipran. Chronic pain [MG30] [14]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Iloprost and Anisindione. Coagulation defect [3B10] [13]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Iloprost and Regorafenib. Colorectal cancer [2B91] [15]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Iloprost and Ardeparin. Coronary thrombosis [BA43] [16]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Iloprost and Danaparoid. Deep vein thrombosis [BD71] [16]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Iloprost and Rivaroxaban. Deep vein thrombosis [BD71] [17]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Iloprost and Sertraline. Depression [6A70-6A7Z] [14]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Iloprost and Vilazodone. Depression [6A70-6A7Z] [14]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Iloprost and Isocarboxazid. Depression [6A70-6A7Z] [18]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Iloprost and Milnacipran. Depression [6A70-6A7Z] [14]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Iloprost and Escitalopram. Depression [6A70-6A7Z] [14]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Iloprost and Desvenlafaxine. Depression [6A70-6A7Z] [14]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Iloprost and Clomipramine. Depression [6A70-6A7Z] [14]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Iloprost and Heme. Discovery agent [N.A.] [19]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Iloprost and Apigenin. Discovery agent [N.A.] [20]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Iloprost and Avapritinib. Gastrointestinal stromal tumour [2B5B] [15]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Iloprost and Sulfinpyrazone. Gout [FA25] [13]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Iloprost and Procarbazine. Hodgkin lymphoma [2B30] [18]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Iloprost and Acalabrutinib. Mature B-cell lymphoma [2A85] [21]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Iloprost and Ibrutinib. Mature B-cell lymphoma [2A85] [22]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Iloprost and Ponatinib. Mature B-cell lymphoma [2A85] [23]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Iloprost and Panobinostat. Multiple myeloma [2A83] [24]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Iloprost and Ozanimod. Multiple sclerosis [8A40] [18]
Fedratinib DM4ZBK6 Moderate Increased risk of bleeding by the combination of Iloprost and Fedratinib. Myeloproliferative neoplasm [2A20] [13]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Iloprost and Dasatinib. Myeloproliferative neoplasm [2A20] [25]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Iloprost and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [26]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Iloprost and Prasugrel. Myocardial infarction [BA41-BA43] [13]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Iloprost and Vorapaxar. Myocardial infarction [BA41-BA43] [13]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Iloprost and Sibutramine. Obesity [5B80-5B81] [14]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Iloprost and Dexfenfluramine. Obesity [5B80-5B81] [14]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Iloprost and Nepafenac. Osteoarthritis [FA00-FA05] [27]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Iloprost and MK-4827. Ovarian cancer [2C73] [15]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Iloprost and Safinamide. Parkinsonism [8A00] [18]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Iloprost and Rasagiline. Parkinsonism [8A00] [18]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Iloprost and Choline salicylate. Postoperative inflammation [1A00-CA43] [13]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Iloprost and Salsalate. Rheumatoid arthritis [FA20] [13]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Iloprost and Plicamycin. Testicular cancer [2C80] [13]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Iloprost and Caplacizumab. Thrombocytopenia [3B64] [13]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Iloprost and Apixaban. Thrombosis [DB61-GB90] [15]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Iloprost and Cangrelor. Thrombosis [DB61-GB90] [13]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Iloprost and Brilinta. Thrombosis [DB61-GB90] [15]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Iloprost and Cabozantinib. Thyroid cancer [2D10] [28]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Iloprost and Betrixaban. Venous thromboembolism [BD72] [29]
⏷ Show the Full List of 45 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1966).
2 Iloprost FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
7 Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
8 Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
9 Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology. 2006 Apr;147(4):1697-705. doi: 10.1210/en.2005-1073. Epub 2005 Dec 22.
10 Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res. 2010 Jul 23;107(2):252-62. doi: 10.1161/CIRCRESAHA.109.209940. Epub 2010 Jun 3.
11 The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis. Vasa. 2005 Nov;34(4):243-9. doi: 10.1024/0301-1526.34.4.243.
12 Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem. 2002 Mar;269(6):1714-25. doi: 10.1046/j.1432-1327.2002.02817.x.
13 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
14 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
15 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
17 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
18 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
19 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
20 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
21 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
22 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
23 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
26 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
27 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
28 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
29 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.